We are currently developing safe and simple tests that will be able to educate families and clinicians about the status of pregnancy and the genetic health of the baby as early as five weeks of pregnancy.
As research moves forward, we will provide customers with a 'standard' sampling kit that can be used safely by a health professional to collect and ship a sample.
Samples will be de-identified to protect customer privacy and made accessible according to federal laws and regulations.
Our first set of tests will focus on gender determination and Sickle cell disease. Our test will enable us to determine the gender of the fetus and the genetic carrier status (affected or unaffected) by looking at the DNA of the baby obtained by the pap smear.
ART received federal funding from the National Institute of Health to develop and commercialize tests to improve the life of families and their children by determining the genetic status of the baby early in pregnancy.